Trial
NCT00095576
Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Merck Sharp & Dohme LLC
Collaborators
HIV Vaccine Trials Network
Condition
AIDS
Intervention
Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-10-06